Client Success Story: Over €200 Million! Congratulations to I-Mab Biopharma for Successful Licensing to Sanofi — SHUIMU BIO Powers New Collaboration on CD73 Target Drugs
On September 25, 2024, SHUIMU BIO received exciting news from our client, I-Mab Biopharma: their innovative CD73-targeted cancer therapy has been successfully licensed to Sanofi, with a total deal value exceeding €200 million!
I-Mab Biopharma, a leader in innovative biologics research and development, recently announced a strategic collaboration with global pharmaceutical giant Sanofi. Under this agreement, I-Mab licensed the development, production, and commercialization rights for their proprietary CD73 antibody, uliledlimab, in Greater China to Sanofi. I-Mab is set to receive approximately €32 million in upfront and near-term milestone payments, with a potential total consideration of up to €213 million (approximately 1.7 billion RMB).
The Importance of CD73 Target in Cancer Immunotherapy
The CD73 target plays a crucial role in the tumor micro-environment. By catalyzing the...